2020 Pilot Grants

Chemical/Genetic Screening Epigenetics Institute Pilot Grant Program

The Epigenetics Institute at Penn in collaboration with the High-throughput Screening Core (HTSC) at Penn is announcing a Pilot Grant Program to utilize the expertise and services of the core available to members of the Epigenetics community.  The specific scientific focus of this pilot grant application is non-restrictive, but applications must utilize the services of the HTSC.  Applications with a focus to utilize the cores’ ability to screen either a) FDA approved drugs and known bioactives library or b) siRNA libraries of Gene Ontology (GO) categories or user defined gene sets to identify/validate candidate gene targets are encouraged.  In preparing a proposal, applicants are encouraged to consult with the core directors about the feasibility of a candidate screen, e.g. reporter gene assay, and budget.  Importantly, pilot grants that are responsive to an upcoming RFA, future NIH Concept or other future funding mechanisms will be given priority. The science remains a priority; however, it is important to emphasize how results from utilizing the core’s services will be used to leverage additional funding to support an expanded study.
High-throughput screening core: The Penn High-throughput screening core (HTSC) provides the PSOM community with technical expertise in HTS to identify genes or organic small molecule inhibitors of signaling pathways and cellular phenotypes in models of human disease.  To meet the needs of investigators, the HTS provides advice and assistance with assay developing biological assays (i.e. biochemical-, cell-, and high-content) in miniaturized, multiwell microtiter plates that are laboratory automation compatible for HTS. For a consultation contact David C. Schultz, PhD, Technical Director (dschultz@pennmedicine.upenn.edu).
Award Amount & Duration: Up to $20,000 for a 1-year pilot project.
Award Dates:

  • Application Receipt Deadline: October 25, 2019, at 11:59 pm
  • Notification of Award: November 15, 2019
  • Funding Period: November 25, 2019 – November 25, 2020

2020 Chemical Genetic Screening Epigenetics Pilot RFA

Applications Are Closed

Past At-Large Epigenetics Pilot Grant Awardees

Year(s) AwardedInvestigator(s)Title of Project
2019Irfan A. Asangani, Ph.D.High throughput screening of FDA approved drugs with EZH2 inhibitor in prostate cancer cells
2017Irfan A. Asangani, Ph.D.High throughput screening of FDA approved drugs with EZH2 inhibitor in prostate cancer cells